FDA Cannot Regulate Stem Cell Treatments, DC Circ. Hears

Law360, Washington (October 21, 2013, 5:28 PM EDT) -- Regenerative Sciences LLC on Monday blasted the U.S. Food and Drug Administration's attempt to regulate its stem cell treatments as a drug, telling a D.C. Circuit panel that the agency doesn't have the authority to oversee its medical practices.

Regenerative Sciences' counsel Andrew S. Ittleman accused the agency of trying to gain “limitless authority” over the medical practice by claiming its Regenexx procedure had violated the Federal Food, Drug and Cosmetic Act by shipping its components across state lines.

The Regenexx procedure — which uses a...
To view the full article, register now.

Related

Sections

Case Information

Case Title

USA v. Regenerative Sciences, LLC, et al


Case Number

12-5254

Court

Appellate - DC Circuit

Nature of Suit

1890 Other Statutory Actions

Date Filed

August 16, 2012

Law Firms

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.